What does illumicell AI do?
illumicell AI is a Boston, MA-based techmed startup that is developing a portable lab scanner and a real-time AI platform for fluid-based diagnostics. The platform analyzes cells and biomarkers from various fluids such as semen, urine, and cerebrospinal fluid, providing personalized insights on factors like fertility changes and supplement responses.
How much did they raise?
The company raised $2M in a Pre-Seed funding round. Lead investors included KOFA Healthcare, Harvard Phoenix Venture Fund, MedTechSyndicates, and Dr. Jeremy Teoh, who participated to support early-stage innovation in healthcare technology.
What are their plans for the money?
The funds will be used to accelerate the development of its diagnostic solutions and further clinical trials. With plans to submit to the FDA in 2026, the investment is expected to enhance the platform’s capabilities, potentially transforming diagnostic processes in fluid analysis.
What have they achieved so far?
illumicell AI has already demonstrated promising results in early clinical trials, outperforming legacy systems. The startup’s progress has been recognized by several prestigious innovation programs including Harvard i-Labs, Creative Destruction Lab, MassChallenge, Techstars, and Keihanna KGAP+.
